Nifty Pharma Index dips 1.8% on Trump Tariff concerns: Aurobindo, Cipla, Lupin among key losers
Ujjval Jauhari
Published 6 May 2025, 09:31 AM IST Stock Market Today: Nifty Pharma Index saw shar correction
Stock Market Today: Nifty Pharma Index saw steep cuts of more than 1.8% in the morning trades on Tuesday amidst Trump Tariff concerns: Aurobindo, Cipla, Lupin share prices were among key losers
First Published: 6 May 2025, 09:31 AM IST
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
12 hours ago
- Mint
Afcons Infrastructure share price rises 6% on a large order win from Reliance
Ujjval Jauhari Published 9 Jun 2025, 09:33 AM IST Stock Market Today: Afcons Infrastructure's large order win from Reliance. Stock Market Today: Afcons Infrastructure share price rises 6% during the intraday trades on a large order win from Reliance. The Letter of Award (LoA) from Reliance Industries Limited is worth ₹ 700 crore
Business Standard
13 hours ago
- Business Standard
Lupin gets USFDA nod for Oxcarbazepine ER tablets
Lupin announced that it has received tentative approval from the U.S Food and Drug Administration (US FDA) for its abbreviated new drug application for Oxcarbazepine extended-release (ER) tablets. Oxcarbazepine ER tablets, 150 mg, 300 mg, and 600 mg are bioequivalent to Oxtellar XR ER tablets, 150 mg, 300 mg, and 600 mg, of Supernus Pharmaceuticals, Inc., and are indicated for the treatment of partial-onset seizures in patients 6 years of age and older. This product would be manufactured at Lupins Nagpur facility in India. Oxcarbazepine ER tablets (RLD Oxtellar XR) had estimated annual sales of $206 million in the U.S. (IQVIA MAT April 2025). Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The companys consolidated net profit surged 114.9% to Rs 772.52 crore on 13.6% jump in net sales to Rs 5,562.20 crore in Q4 FY25 over Q4 FY24. The scrip rose 0.20% to end at Rs 1,999.20 on the BSE.
United News of India
a day ago
- United News of India
Lupin gets tentative approval from U.S. FDA for Oxcarbazepine ER Tablets
Hyderabad, June 7 (UNI) Global pharma major Lupin Limited (Lupin) announced on Saturday that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Oxcarbazepine Extended-Release (ER) Tablets, 150 mg, 300 mg, and 600 mg. This product would be manufactured at Lupin's Nagpur facility in India, the Pharma company said in a release. Oxcarbazepine ER Tablets, 150 mg, 300 mg, and 600 mg are bioequivalent to Oxtellar XR® ER Tablets, 150 mg, 300 mg, and 600 mg, of Supernus Pharmaceuticals, Inc., and are indicated for the treatment of partial-onset seizures in patients 6 years of age and older. Oxcarbazepine ER Tablets (RLD Oxtellar XR®) had estimated annual sales of USD 206 million in the U.S. (IQVIA MAT April 2025). UNI KNR BM
